PL370478A1 - Pochodne aminoindazolu jako inhibitory kinaz białkowych - Google Patents

Pochodne aminoindazolu jako inhibitory kinaz białkowych

Info

Publication number: PL370478A1
Authority: PL; Poland
Prior art keywords: protein; kinase inhibitors; aminoindazole derivatives; aminoindazole; derivatives
Prior art date: 2002-03-11

Application number

PL03370478A

Other languages

English (en)

Inventor

Gilles Dutruc-Rosset

Dominique Lesuisse

Thomas Rooney

Franck Halley

Original Assignee

Aventis Pharma S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-03-11

Filing date

2003-03-07

Publication date

2005-05-30

2003-03-07 Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.

2005-05-30 Publication of PL370478A1 publication Critical patent/PL370478A1/pl

Links

YDTDKKULPWTHRV-UHFFFAOYSA-N 1H-indazol-3-amine Chemical class C1=CC=C2C(N)=NNC2=C1 YDTDKKULPWTHRV-UHFFFAOYSA-N 0.000 title 1
229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
239000003909 protein kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Immunology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Emergency Medicine (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Child & Adolescent Psychology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL03370478A 2002-03-11 2003-03-07 Pochodne aminoindazolu jako inhibitory kinaz białkowych PL370478A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0202997A FR2836915B1 (fr)	2002-03-11	2002-03-11	Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number	Publication Date
PL370478A1 true PL370478A1 (pl)	2005-05-30

Family

ID=27763685

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL03370478A PL370478A1 (pl)	2002-03-11	2003-03-07	Pochodne aminoindazolu jako inhibitory kinaz białkowych

Country Status (30)

Country	Link
US (1)	US6949579B2 (pl)
EP (1)	EP1487804B1 (pl)
JP (2)	JP4648630B2 (pl)
KR (1)	KR101068770B1 (pl)
CN (2)	CN101962365A (pl)
AR (1)	AR038915A1 (pl)
AU (1)	AU2003242809B8 (pl)
BR (1)	BR0308373A (pl)
CA (1)	CA2478542C (pl)
FR (1)	FR2836915B1 (pl)
GT (1)	GT200300057A (pl)
HR (1)	HRP20040824B1 (pl)
IL (2)	IL163831A0 (pl)
JO (1)	JO2326B1 (pl)
MA (1)	MA27230A1 (pl)
ME (2)	ME00058B (pl)
MX (1)	MXPA04007478A (pl)
MY (1)	MY138269A (pl)
NO (1)	NO329384B1 (pl)
NZ (1)	NZ535147A (pl)
PA (1)	PA8568301A1 (pl)
PE (1)	PE20040155A1 (pl)
PL (1)	PL370478A1 (pl)
RS (1)	RS52396B (pl)
RU (1)	RU2345070C2 (pl)
SV (1)	SV2003001494A (pl)
TW (1)	TWI329103B (pl)
UY (1)	UY27713A1 (pl)
WO (1)	WO2003078403A2 (pl)
ZA (1)	ZA200406687B (pl)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2836914B1 (fr)	2002-03-11	2008-03-14	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
EP1506176B1 (en) *	2002-05-17	2013-04-24	Pfizer Italia S.r.l.	Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2004022544A1 (fr) *	2002-09-05	2004-03-18	Aventis Pharma S.A.	Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
BR0316950A (pt) *	2002-12-02	2006-01-17	Hoffmann La Roche	Derivados de indazol como antagonistas de crf
MXPA05005554A (es) *	2002-12-12	2005-07-26	Aventis Pharma Sa	Derivados de aminoindazol y su utilizacion como inhibidores de quinasas.
FR2848554A1 (fr) *	2002-12-12	2004-06-18	Aventis Pharma Sa	Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
US7135575B2 (en)	2003-03-03	2006-11-14	Array Biopharma, Inc.	P38 inhibitors and methods of use thereof
JP4734119B2 (ja) *	2004-02-12	2011-07-27	田辺三菱製薬株式会社	インダゾール化合物及びその医薬用途
FR2871158A1 (fr) *	2004-06-04	2005-12-09	Aventis Pharma Sa	Indazoles substitues, compositions les contenant, procede de fabrication et utilisation
US7592363B2 (en)	2004-08-03	2009-09-22	Wyeth	Indazoles
EP1931641B1 (en)	2005-09-09	2010-08-25	Schering Corporation	NOVEL 4-CYANO, 4-AMINO, AND 4-AMINOMETHYL DERIVATIVES OF PYRAZOLO[1,5-a]PYRIDINES, PYRAZOLO[1,5-c]PYRIMIDINES AND 2H-INDAZOLE COMPOUNDS AND 5-CYANO, 5-AMINO, AND 5-AMINOMETHYL DERIVATIVES OF IMIDAZO[1,2-a]PYRIDINES, AND IMIDAZO[1,5-a]PYRAZINES COMPOUNDS AS CYCLIN DEPENDENT KINASE INHI
SI1981851T1 (sl)	2006-01-31	2012-05-31	Array Biopharma Inc	Kinazni inhibitorji in postopki za njihovo uporabo
AU2007283113A1 (en)	2006-08-08	2008-02-14	Sanofi-Aventis	Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
ES2509820T3 (es) *	2006-12-20	2014-10-20	Nerviano Medical Sciences S.R.L.	Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer
DE102007022565A1 (de) *	2007-05-14	2008-11-20	Merck Patent Gmbh	Heterocyclische Indazolderivate
EA018503B1 (ru) *	2007-07-20	2013-08-30	НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л.	Замещенные производные индазола, активные как ингибиторы киназы
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009094427A1 (en)	2008-01-23	2009-07-30	Bristol-Myers Squibb Company	4-pyridinone compounds and their use for cancer
UY31968A (es)	2008-07-09	2010-01-29	Sanofi Aventis	Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8354399B2 (en) *	2008-12-18	2013-01-15	Nerviano Medical Sciences S.R.L.	Substituted indazole derivatives active as kinase inhibitors
CN102459253B (zh)	2009-04-30	2015-03-25	葛兰素集团有限公司	作为pi3-激酶抑制剂的*唑取代的吲唑化合物
KR20120060207A (ko)	2009-08-26	2012-06-11	사노피	신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
US9180127B2 (en)	2009-12-29	2015-11-10	Dana-Farber Cancer Institute, Inc.	Type II Raf kinase inhibitors
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
CN103080093A (zh) *	2010-03-16	2013-05-01	达纳－法伯癌症研究所公司	吲唑化合物及其应用
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
JP5937102B2 (ja)	2010-12-14	2016-06-22	エレクトロフォレティクスリミテッド	カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤
EP2766349B1 (de)	2011-03-08	2016-06-01	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en)	2011-03-08	2014-08-19	Sanofi	Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de)	2011-03-08	2014-12-17	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120058A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2567959B1 (en)	2011-09-12	2014-04-16	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9056867B2 (en)	2011-09-16	2015-06-16	Novartis Ag	N-substituted heterocyclyl carboxamides
WO2013045413A1 (en)	2011-09-27	2013-04-04	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CA2856291C (en)	2011-11-17	2020-08-11	Dana-Farber Cancer Institute, Inc.	Inhibitors of c-jun-n-terminal kinase (jnk)
EP2797879B1 (en) *	2011-12-27	2018-12-26	Bio-Pharm Solutions Co., Ltd.	Phenyl carbamate compounds for use in alleviating or treating pain and neuropathic pain
EP2909194A1 (en)	2012-10-18	2015-08-26	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en)	2012-10-19	2017-09-12	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en)	2012-10-19	2014-04-24	Dana-Farber Cancer Institute, Inc.	Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
AU2014337122B2 (en)	2013-10-18	2019-01-03	Dana-Farber Cancer Institute, Inc.	Heteroaromatic compounds useful for the treatment of proliferative diseases
US10047070B2 (en)	2013-10-18	2018-08-14	Dana-Farber Cancer Institute, Inc.	Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
CN103739550B (zh) *	2014-01-02	2016-06-01	中国药科大学	2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
SG11201605917SA (en) *	2014-01-24	2016-08-30	Abbvie Inc	6-phenyl- or 6-(pyridin-3-yl)indazole derivatives and methods of use
TWI672141B (zh)	2014-02-20	2019-09-21	美商醫科泰生技	投予ｒｏｓ１突變癌細胞之分子
WO2015164614A1 (en)	2014-04-23	2015-10-29	Dana-Farber Cancer Institute, Inc.	Janus kinase inhibitors and uses thereof
US9862688B2 (en)	2014-04-23	2018-01-09	Dana-Farber Cancer Institute, Inc.	Hydrophobically tagged janus kinase inhibitors and uses thereof
KR101731624B1 (ko) *	2014-07-01	2017-05-04	광주과학기술원	세포 리프로그래밍 유도용 조성물
CN105524048B (zh) *	2014-08-19	2019-11-12	上海海和药物研究开发有限公司	作为fgfr激酶抑制剂的吲唑类化合物及其制备和应用
CN107207471B (zh)	2014-12-02	2020-06-26	伊尼塔公司	用于治疗神经母细胞瘤的组合
WO2016096709A1 (en)	2014-12-16	2016-06-23	Eudendron S.R.L.	Heterocyclic derivatives modulating activity of certain protein kinases
EP3236959B1 (en)	2014-12-23	2025-09-24	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 (cdk7)
AU2016243529B2 (en)	2015-03-27	2021-03-25	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
CN106279119B (zh) *	2015-05-27	2020-06-16	上海海和药物研究开发有限公司	一种新型激酶抑制剂的制备及其应用
US10702527B2 (en)	2015-06-12	2020-07-07	Dana-Farber Cancer Institute, Inc.	Combination therapy of transcription inhibitors and kinase inhibitors
GB201511382D0 (en)	2015-06-29	2015-08-12	Imp Innovations Ltd	Novel compounds and their use in therapy
EP4019515A1 (en)	2015-09-09	2022-06-29	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinases
MX2018004879A (es) *	2015-10-22	2019-02-28	Selvita S A	Nuevos derivados de piridona y su uso como inhibidores de quinasas.
CN105467027B (zh) *	2015-11-18	2021-09-21	北京万全德众医药生物技术有限公司	一种用气相色谱法分离测定米诺膦酸中间体有关物质的方法
JP7061068B2 (ja)	2015-12-18	2022-04-27	イグナイタインコーポレイテッド	癌治療のための併用薬
CN121401264A (zh)	2017-07-19	2026-01-27	伊尼塔公司	包括恩曲替尼的药物组合物
US10392368B2 (en)	2017-08-01	2019-08-27	Theravance Biopharma R&D Ip, Llc	Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors
WO2019077506A1 (en)	2017-10-17	2019-04-25	Ignyta, Inc.	PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS
CN110117278B (zh) *	2018-02-07	2022-07-19	石家庄以岭药业股份有限公司	烷氧基苯并五元(六元)杂环胺类化合物及其药物用途
JP7590185B2 (ja)	2018-06-25	2024-11-26	ダナ－ファーバーキャンサーインスティテュート，インコーポレイテッド	Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用
WO2020033919A1 (en)	2018-08-10	2020-02-13	Diapin Therapeutics, Llc	Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
US12172995B2 (en)	2018-10-24	2024-12-24	Bristol-Myers Squibb Company	Substituted indole and indazole compounds
ES2963696T3 (es)	2018-10-24	2024-04-01	Bristol Myers Squibb Co	Compuestos diméricos de indol sustituidos
AU2019413694B2 (en)	2018-12-28	2025-03-20	Dana-Farber Cancer Institute, Inc.	Inhibitors of cyclin-dependent kinase 7 and uses thereof
CA3125039A1 (en)	2019-01-23	2020-07-30	Theravance Biopharma R&D Ip, Llc	Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors
US12187723B2 (en)	2019-05-09	2025-01-07	Bristol-Myers Squibb Company	Substituted benzimidazolone compounds
CN114761404B (zh)	2019-10-01	2025-02-21	百时美施贵宝公司	经取代的双环杂芳基化合物
JP7545467B2 (ja)	2019-10-04	2024-09-04	ブリストル－マイヤーズスクイブカンパニー	置換カルバゾール化合物
WO2021110891A1 (en) *	2019-12-04	2021-06-10	Syngenta Crop Protection Ag	Pesticidally active fused bicyclic heteroaromatic amino compounds
WO2025175264A1 (en) *	2024-02-17	2025-08-21	Padarn Therapeutics, Inc.	Inhibitors of cdk2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3133081A (en) *		1964-05-12		J-aminoindazole derivatives
US2971842A (en) *	1956-03-21	1961-02-14	Gen Aniline & Film Corp	Light sensitive layers for photomechanical reproduction
DE1280878B (de) *	1961-11-30	1968-10-24	Smith Kline French Lab	3-Aminoindazole
GB965511A (en) *	1961-11-30	1964-07-29	Smith Kline French Lab	Improvements in or relating to 3-aminoindazole derivatives
BE626284A (pl) *	1962-04-28
DE1301319B (de) *	1965-09-08	1969-08-21	Siegfried Ag	3,5-Diaminoindazol, dessen Salze, sowie Verfahren zu deren Herstellung
US3720671A (en) *	1970-10-05	1973-03-13	Ciba Geigy Ag	Polycyclic dyestuffs
FR2111641A2 (en) *	1970-10-09	1972-06-09	Geigy Ag J R	Polycyclic cpds as dispersion dyestuffs for - hydrophobic organic fibres
DE2458965C3 (de) *	1974-12-13	1979-10-11	Bayer Ag, 5090 Leverkusen	3-Amino-indazol-N-carbonsäure-Derivate, Verfahren zu ihrer Herstellung sowie sie enthaltende Arzneimittel
JPS51143010A (en) *	1975-06-04	1976-12-09	Kao Corp	Stable bleaching detergent composition
SU742430A1 (ru) *	1978-11-09	1980-06-25	Предприятие П/Я А-7850	Способ получени 3-амино-5-нитроиндазола
JPS58159473A (ja) *	1982-03-17	1983-09-21	Asahi Chem Ind Co Ltd	ベンゼン環置換基を有する新規な１位置換インダゾ−ル誘導体およびその製造法
EP0090972B1 (en) *	1982-03-17	1990-05-30	Asahi Kasei Kogyo Kabushiki Kaisha	Indazole derivatives
KR940021073A (ko) *	1993-03-02	1994-10-17	미야베 요시가즈	알쯔하이머병의 예방 또는 치료제, 그 스크리닝 방법 및 인간 유래의 타우 단백질 키나아제 i
KR100423899B1 (ko) *	2000-05-10	2004-03-24	주식회사 엘지생명과학	세포 증식 억제제로 유용한 1,1-디옥소이소티아졸리딘을갖는 인다졸

2002
- 2002-03-11 FR FR0202997A patent/FR2836915B1/fr not_active Expired - Fee Related
2003
- 2003-02-28 PA PA20038568301A patent/PA8568301A1/es unknown
- 2003-03-03 SV SV2003001494A patent/SV2003001494A/es not_active Application Discontinuation
- 2003-03-06 TW TW092104839A patent/TWI329103B/zh not_active IP Right Cessation
- 2003-03-06 JO JO200323A patent/JO2326B1/en active
- 2003-03-07 NZ NZ535147A patent/NZ535147A/en not_active IP Right Cessation
- 2003-03-07 MX MXPA04007478A patent/MXPA04007478A/es active IP Right Grant
- 2003-03-07 CN CN2010102771547A patent/CN101962365A/zh active Pending
- 2003-03-07 CN CNA038053667A patent/CN1656078A/zh active Pending
- 2003-03-07 BR BR0308373-0A patent/BR0308373A/pt not_active IP Right Cessation
- 2003-03-07 JP JP2003576409A patent/JP4648630B2/ja not_active Expired - Fee Related
- 2003-03-07 WO PCT/FR2003/000752 patent/WO2003078403A2/fr not_active Ceased
- 2003-03-07 ME MEP-2008-161A patent/ME00058B/me unknown
- 2003-03-07 PL PL03370478A patent/PL370478A1/pl unknown
- 2003-03-07 KR KR1020047014199A patent/KR101068770B1/ko not_active Expired - Fee Related
- 2003-03-07 AU AU2003242809A patent/AU2003242809B8/en not_active Ceased
- 2003-03-07 CA CA2478542A patent/CA2478542C/fr not_active Expired - Fee Related
- 2003-03-07 HR HRP20040824AA patent/HRP20040824B1/hr not_active IP Right Cessation
- 2003-03-07 RS YU79504A patent/RS52396B/sr unknown
- 2003-03-07 RU RU2004129780/04A patent/RU2345070C2/ru not_active IP Right Cessation
- 2003-03-07 EP EP03744396.7A patent/EP1487804B1/fr not_active Expired - Lifetime
- 2003-03-07 PE PE2003000234A patent/PE20040155A1/es not_active Application Discontinuation
- 2003-03-07 IL IL16383103A patent/IL163831A0/xx unknown
- 2003-03-07 ME MEP-161/08A patent/MEP16108A/xx unknown
- 2003-03-10 AR ARP030100808A patent/AR038915A1/es unknown
- 2003-03-11 UY UY27713A patent/UY27713A1/es unknown
- 2003-03-11 US US10/385,871 patent/US6949579B2/en not_active Expired - Lifetime
- 2003-03-11 MY MYPI20030839A patent/MY138269A/en unknown
- 2003-03-11 GT GT200300057A patent/GT200300057A/es unknown
2004
- 2004-08-05 MA MA27814A patent/MA27230A1/fr unknown
- 2004-08-23 ZA ZA2004/06687A patent/ZA200406687B/en unknown
- 2004-08-31 IL IL163831A patent/IL163831A/en not_active IP Right Cessation
- 2004-09-29 NO NO20044137A patent/NO329384B1/no not_active IP Right Cessation
2010
- 2010-04-06 JP JP2010087830A patent/JP5315287B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
TWI329103B (en)	2010-08-21
RU2004129780A (ru)	2005-04-10
CN1656078A (zh)	2005-08-17
CA2478542A1 (fr)	2003-09-25
IL163831A0 (en)	2005-12-18
KR101068770B1 (ko)	2011-09-30
US6949579B2 (en)	2005-09-27
FR2836915A1 (fr)	2003-09-12
GT200300057A (es)	2006-10-19
NZ535147A (en)	2007-08-31
JO2326B1 (en)	2006-06-28
MXPA04007478A (es)	2004-11-10
EP1487804B1 (fr)	2014-02-26
FR2836915B1 (fr)	2008-01-11
JP5315287B2 (ja)	2013-10-16
NO329384B1 (no)	2010-10-11
CN101962365A (zh)	2011-02-02
MA27230A1 (fr)	2005-02-01
WO2003078403A2 (fr)	2003-09-25
IL163831A (en)	2010-12-30
UY27713A1 (es)	2003-09-30
EP1487804A2 (fr)	2004-12-22
RS79504A (sr)	2006-12-15
SV2003001494A (es)	2003-07-10
US20040014802A1 (en)	2004-01-22
JP2010222357A (ja)	2010-10-07
AU2003242809B8 (en)	2010-04-15
ZA200406687B (en)	2005-10-26
KR20040091121A (ko)	2004-10-27
TW200403226A (en)	2004-03-01
PE20040155A1 (es)	2004-04-18
MEP16108A (en)	2010-06-10
CA2478542C (fr)	2012-02-21
WO2003078403A3 (fr)	2004-04-22
HRP20040824B1 (hr)	2013-05-31
RS52396B (sr)	2013-02-28
NO20044137L (no)	2004-11-25
JP2005530711A (ja)	2005-10-13
AU2003242809B2 (en)	2010-03-18
AU2003242809A1 (en)	2003-09-29
HRP20040824A2 (en)	2005-06-30
MY138269A (en)	2009-05-29
JP4648630B2 (ja)	2011-03-09
AR038915A1 (es)	2005-02-02
BR0308373A (pt)	2005-01-11
RU2345070C2 (ru)	2009-01-27
ME00058B (me)	2010-10-10
PA8568301A1 (es)	2005-02-04

Publication	Publication Date	Title
PL370478A1 (pl)	2005-05-30	Pochodne aminoindazolu jako inhibitory kinaz białkowych
IL165515A0 (en)	2006-01-15	Bisindolyl-maleimid derivatives as kinase inhibitors
AP2048A (en)	2009-09-24	Diazepinoindole derivatives as kinase inhibitors
PL376129A1 (pl)	2005-12-12	Pochodne pirydazynonu jako inhibitory GSK-3BETA
SI1492785T1 (sl)	2009-06-30	2-hidroksi-3-heteroarilindolni derivati kot inhibitorji GSK3
IL169691A0 (en)	2007-07-04	Malonamide derivatives as gamma-secretase inhibitors
AU2003293356A8 (en)	2004-03-19	Dihydropyridinone derivatives as hne inhibitors
AU2003271566A8 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
ZA200508359B (en)	2009-02-25	Indazole derivatives as JNK inhibitors
IL172132A0 (en)	2006-04-10	Thienopyridone derivatives as kinase inhibitors
AU2003278088A1 (en)	2004-05-25	Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors
ZA200702394B (en)	2008-11-26	Indozolone derivatives as 11b-HSD1 inhibitors
IS7717A (is)	2005-02-28	Pýrídasínónafleiður sem PDF4-hemlar
AU2003301302A1 (en)	2004-05-04	Pyradazine compounds as gsk-3 inhibitors
ZA200700181B (en)	2009-03-25	Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
EP1551801A4 (en)	2007-06-20	NOVEL GAMMA-LACTAMES AS INHIBITORS OF BETA-SECRETASE
PL376789A1 (pl)	2006-01-09	Pochodne aminoindazoli i ich zastosowanie jako inhibitorów kinazy
AU2003302238A8 (en)	2004-06-23	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
AU2003249531A1 (en)	2004-02-25	Azaisoquinoline derivatives as matrix metalloproteinase inhibitors
AU2003250482A1 (en)	2004-02-25	Phthalimide derivatives as matrix metalloproteinase inhibitors
IL172375A0 (en)	2009-02-11	Chinazoline derivatives as aurora kinase inhibitors
IL175106A0 (en)	2006-09-05	Novel keto-oxadiazole derivatives as cathepsin inhibitors
AU2003215635A1 (en)	2003-10-13	Thiazol-2-yl-imine compounds as pde-7 inhibitors
AU2003242559A1 (en)	2003-12-19	Alkylaminosiloxanes as corrosion inhibitors
AU2003260908A1 (en)	2004-04-19	Pyrazole derivatives as reverse transcriptase inhibitors